How Do our Genes Affect an LSD TRIP?? New MindMed Study [ MMED / MNMD ]

Does our Genetic makeup influence our LSD trip? Hey psychedelic Investors! MindMed ( MMED/MNMD/MMQ ) recently published a study in Nature Scientific Reports examining the different variations in our genes and how they affect one's experience during an LSD trip. The results are leading us to infer that, soon, we might be able to predict the strength, duration and perhaps even the subjective experience one undergoes when taking LSD based on certain genes that we possesses. If we're able to do that, how will this affect LSD’s medical uses in therapy setting? Can we use this knowledge to move towards personalized dosing, where each individual will receive a different dose level for the same procedure, based on what their genetic code tells the therapist? We will answer these questions in today's episode . We will also take a deep dive into the LSD study itself and explain why the findings are important for the future of psychedelic-assisted psychotherapy. Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor Email: thepsychedelicinvestor@gmail.com Facebook: @thepsychedelicinvestor editing: @themyaholy Music: www.bensound.com https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #MindMed #MindMedNews #MindMedstock

HAVN’s Cluster Headache Treatment BETTER Than Mindmed’s? (HAVN CEO Interview)

HAVN VS. Mindmed - Whose Cluster Headache Treatment Is Better? Havn Life Sciences, (CSE: HAVN / OTC: HAVLF / FRA: 5NP) has started to be mentioned more and more on this channel, particularly in our "This Week In Psychedelic Stocks" segment. In light of HAVN's recent news that it is entering the cluster headaches segment, we are having a discussion with the company CEO, Tim Moore. HAVN is focused on standardizing extraction of psychoactive compounds, the development of natural health products, and developing innovative mental health treatment to support brain health and enhance the capabilities of the mind. Interestingly enough, HAVN Labs is of the first companies to receive permission from Health Canada to work with psilocybin in 2020. The global functional food market is expected to reach $34.3 Billion USD by 2024, registering a CAGR of 8.04% during the forecast period (2019-2024) and is expected to experience huge demand for Reishi and Cordyceps. This is why HAVN Life has decided to pursue formulations with these mushrooms. DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. Full Disclosure: This video is for entertainment only and shouldn't be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor and a third party. The Psychedelic Investor has been hired for a period beginning on 29,06,2021 and ending on 29,06,2021 to publicly disseminate information about (HAVN) via digital communications. We have been paid ($1000) . https://havnlife.com/ CSE: HAVN | OTC: HAVLF | FRA: 5NP #HAVN #HAVNLifeSciences #Mindmed
'PSY' Becomes First U.S.-Listed Psychedelic ETF

‘PSY’ Becomes First U.S.-Listed Psychedelic ETF

Defiance Next Gen Altered Experience ETF began trading Friday on the New York Stock Exchange under the symbol PSY.

MindMed Insiders DUMP Shares…AGAIN. Should we be Worried?

Here are my thoughts on MindMed's CEO Jr Rahn and Board member Bruce Linton's recent shares sell-off. Resources: How much JR sold from MMED/ MNMD: https://thedeepdive.ca/mind-medicine-sees-ceo-sell-24-7-million-in-company-stock/ Stated reason for the sale: https://twitter.com/PsilocybinAlpha/status/1397951345240461313/photo/1 How much MindMed stock JR Sold in the past: https://seekingalpha.com/article/4411079-mind-medicine-great-potential-questionable-business-model Insider selling SEC rules: Sec rule regulation: https://www.investopedia.com/terms/r/rule-10b5-1.asp Canada and the SEC: https://sec.report/CIK/0000230098 MindMed's compensation packages as published on April 27, 2021 https://www.sedar.com/GetFile.do?lang=EN&docClass=10&issuerNo=00030583&issuerType=03&projectNo=03209908&docId=4942116 Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor Email: thepsychedelicinvestor@gmail.com Facebook: @thepsychedelicinvestor Music: www.bensound.com https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor bruce linton image: https://www.rollingstone.com/culture/culture-news/bruce-linton-canopy-growth-ceo-fired-marijuana-855361/ DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #MindMed #MindMedNews #MindMedstock

Psychedelic Capital Conference – How to Watch FREE [ I Just Made the BIG LEAGUES]

https://microdose.buzz/JAMESH Hey guys! as mentioned in our previous episode, I will be participating in the Psychedelic Capital Conference as a panel member! This is a monthly conference run by Microdose.buzz and it's one of the most prestigious events where experts in the fields of investing and psychedelics, as well as industry insiders and leading companies all come together to discuss the topic of investing in psychedelic medicines. The event will take place on Monday May 31st, from 1:30PM to 5:10pmPM EST but you can just tune into my segment, which will be a 30 minute panel discussion, which will start at 2:20 PM. Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @thepsychedelicinvestor Email: thepsychedelicinvestor@gmail.com Facebook: @thepsychedelicinvestor Music: www.bensound.com Video editing: @themyaholy https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #MindMed #PsychedelicStocks #PsychedelicConference https://microdose.buzz/
Psychedelic Business Spotlight: May 8, 2021

Psychedelic Business Spotlight: May 28, 2021

,
This week in psychedelic business news: NeonMind's Medical Advisory Board, Mynd's public listing, and a new study supports novel use of DMT.
Psychedelic Platform Field Trip Health Gets Uplisting Conditional Approval for Toronto Stock Exchange

Psychedelic Platform Field Trip Health Gets Uplisting Conditional Approval for Toronto Stock Exchange

Psychedelic healing platform Field Trip Health has received conditional approval to uplist to the Toronto Stock Exchange.
Psychedelic Drug Development Company Mynd Life Sciences Goes Public on the CSE

Psychedelic Drug Development Company Mynd Life Sciences Goes Public on the CSE

Psychedelic drug development company Mynd Life Sciences has gone public on the CSE.

MindMed Facing Competition From HAVN? Plus Financials and Phase 2 Trials (MNMD, CYBIN, HAVN, MYCO)

Hey guys! In this week’s industry specific news, we’ll cover some interesting developments for MindMed, Mydecine, Cybin, HAVN, and a private company called WAKE. One of the biggest highlights is that HAVN might enter in direct competition with MindMed by penetrating the cluster headaches market. Stay tuned till the end the hear more on this specific news! Timestamps: 0:00 - Intro 1:00 - MindMed Begins a Mescaline Study 4:35 - MindMed & The Chopra Foundation 8:30 - Cybin Progresses Phase 2a psilocybin study 11:56 - Mydecine announces Q1 Financials 14:16 - Havn Life Sciences enters the Cluster Headaches Game 16:30 - Wake Receives First-Ever Approval for Psilocybin for Anxiety & Depression Enjoy! Links: MindMed (MNMD/ MMED / MMQ)) Begins a Mescaline Study: https://mindmed.co/news/press-release/mindmed-announces-the-approval-of-mescaline-study/ MindMed Partners Up with The Chopra foundation: https://mindmed.co/news/press-release/the-chopra-foundation-and-mindmed-enter-into-letter-of-intent-to-partner-on-the-future-of-psychedelic-medicines-mental-wellbeing/ Cybin (CYBN) Progresses Phase IIa psilocybin film strip study: https://www.clinicaltrialsarena.com/news/cybin-phase-ii-psilocybin/ Mydecine (MYCO / MYCOF) Q1 Financials: https://psilocybinalpha.com/news/mydecine-reports-first-quarter-2021-financial-results-and-provides-business-update Havn Life Sciences (HAVN/ HAVLF/ 5NP) Begins to Study Cluster Headaches https://havnlife.com/havn-life-enters-into-agreement-to-acquire-clinical-stage-ip-for-development-of-lsd-derived-api-for-cluster-headaches/ Wake Receives First-Ever Approval for Psilocybin Microdose Study for Anxiety and Depression https://psychedelicspotlight.com/wake-psilocybin-microdose-study/ Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @thepsychedelicinvestor Email: thepsychedelicinvestor@gmail.com Facebook: @thepsychedelicinvestor Music: www.bensound.com Video editing: @themyaholy https://benzinga.grsm.io/jameshallifa... https://benzinga.grsm.io/thepsychedel... DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #MindMed #PsychedelicStocks #HAVN
Enveric Biosciences Acquires Psychedelic Drug Discovery Platform MagicMed Industries

Enveric Biosciences Acquires Psychedelic Drug Discovery Platform MagicMed Industries

Cannabis-focused Enveric Biosciences will acquire Canadian psychedelic drug discovery platform MagicMed Industries.